Cohance Lifesciences Receives OAI Classification from FDA Following GMP Inspection at Hyderabad Facility
核心洞察
Cohance Lifesciences (搜索) received an Official Action Indicated (OAI) classification from the USFDA (搜索) for its finished dosage formulations manufacturing facility in Nacharam, Hyderabad following a GMP inspection.
The inspection conducted from August 4-12, 2025 initially resulted in a Form 483 with six observations, prompting the company to initiate a comprehensive remediation program.
The affected facility contributed less than 2% of the company's consolidated revenues in FY2025, with EBITDA contribution below 1%, minimizing expected material impact on operations.
Cohance Lifesciences (搜索) has received an Official Action Indicated (OAI) classification from the United States Food and Drug Administration (搜索) (USFDA (搜索)) for its Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) located in Nacharam, Hyderabad. The classification follows a Good Manufacturing Practices (GMP) inspection conducted from August 4 to August 12, 2025, excluding the weekend of August 9 and 10.
Regulatory Response and Remediation Efforts
The company initially received a Form 483 from the USFDA (搜索) in August with six observations. In response to the OAI classification, Cohance Lifesciences (搜索) has initiated a comprehensive remediation program and is engaging proactively with the USFDA to align the facility fully with global standards.
"We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets," the company stated in a BSE filing.
Limited Financial Impact Expected
The financial implications of the OAI classification appear minimal for Cohance Lifesciences (搜索). As clarified by the company on September 18, 2025, the US revenue from the Nacharam formulation unit contributed less than 2% of the company's consolidated revenues in FY2025, with related EBITDA contribution below 1%. This limited contribution suggests the regulatory action is not expected to have any material impact on the company's ongoing operations or supplies.
Continued Operations
Despite the OAI classification, the FDF Unit-1 facility at Nacharam continues to run its operations normally. The company maintains its commitment to manufacturing and supplying pharmaceutical products while addressing the regulatory concerns identified during the inspection.